after enrollment, baseline tests are performed to document the current health status. these may include blood work, imaging scans, and other evaluations needed to confirm the diagnosis of diffuse large b‑cell lymphoma.

based on the study design, you are assigned either to the standard treatment arm or to the arm that adds epcoritamab to standard therapy. the assignment is done by the study team and you are not required to make a choice.

treatment is given in repeated cycles. each cycle begins with an infusion of rituximab administered intravenously at a dose of 375 mg per square meter of body‑surface area. the infusion is performed in a clinical setting under medical supervision.

if you are in the combination arm, a subcutaneous injection of epcoritamab is given at a dose of 48 mg. this injection is placed under the skin and also takes place in the clinic.

the cycle described above is repeated according to the study schedule. each repetition follows the same steps: the rituximab infusion and, when applicable, the epcoritamab injection. the exact number of cycles and the interval between them are defined by the protocol.

throughout the treatment period, you will attend regular clinic visits for safety checks, blood tests, and assessments of how the lymphoma is responding. any side effects are recorded and managed by the study team.

once all planned cycles are completed, a comprehensive evaluation is performed. the primary goal is to determine whether a complete remission has been achieved, meaning no detectable disease remains.

additional measurements are taken to assess progression‑free survival, which tracks the time from the start of the study until disease progression or death.

after the end of treatment, you will continue to have scheduled follow‑up visits. these visits monitor long‑term outcomes such as overall survival, disease recurrence, and any late side effects.

the follow‑up period lasts for the duration defined by the study, extending until the final study end date.